Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|A211401||Alliance||Reducing Surgical Complications in Newly Diagnosed Lung Cancer Patients Who Smoke Cigarettes||Cancer Prevention and Control CIRB|
|S1400ANCILLARY||SWOG||Ancillary Study to Evaluate Patient and Physician Attitudes; Knowledge; and Expectations Related to Return of Genomic Results in Cancer in the SWOG 1400 (S1400) Clinical Trial||Adult CIRB - Late Phase Emphasis|
|C80405||CALGB||A Phase III Trial of Irinotecan/5-FU/Leucovorin or Oxaliplatin/5-FU/Leucovorin with Bevacizumab; or Cetuximab (C225); or with the Combination of Bevacizumab and Cetuximab for Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum||Adult CIRB - Late Phase Emphasis||Available to Open|
|DCP-002||NCI||Early Onset Malignancy Initiative (EOMI): Molecular Profiling of Breast; Prostate; Colorectal; Liver; Kidney; and Multiple Myeloma Among Racially and Ethnically Diverse Populations||Adult CIRB - Early Phase Emphasis||Available to Open|
|A041501||Alliance||A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (A Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) with Newly Diagnosed Precursor B-Cell ALL||Adult CIRB - Late Phase Emphasis||Available to Open|
|AOST1322||COG||A Phase II Study of Eribulin (IND# 122686; NSC# 707389) in Recurrent or Refractory Osteosarcoma: An Intergroup NCTN Phase II Study||Pediatric CIRB||Available to Open|
|9947||ETCTN||A Randomized Phase 2 Trial of Cisplatin/Gemcitabine with or without VX-970 in Metastatic Urothelial Carcinoma||Adult CIRB - Early Phase Emphasis||Available to Open|
|ACNS0334||COG||A Phase III Randomized Trial for the Treatment of Newly Diagnosed Supratentorial PNET and High Risk Medulloblastoma in Children < 36 months Old with Intensive Induction Chemotherapy with Methotrexate Followed by Consolidation with Stem Cell Rescue vs. the Same Therapy Without Methotrexate: A Phase III Group-Wide Study||Pediatric CIRB||Available to Open|
|ANBL1531||COG||A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Standard Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL) (IND# 134379)||Pediatric CIRB||Available to Open|
|EA5142||ECOG-ACRIN||Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers||Adult CIRB - Late Phase Emphasis||Available to Open|